Agomab Therapeutics AGMB
NASDAQ AGMB
$11.42 -0.28 (-2.39%)
As of: Sep 22, 2026 · 11:31 AM EDT

Agomab Therapeutics NV (AGMB) Total Debt (2025 - 2026)

Agomab Therapeutics (AGMB) posted Total Debt of $7.8 million for Q2 2026, up 3.08% on a QoQ basis from $7.6 million in Q4 2025.

Analysis

Agomab Therapeutics NV (AGMB) Total Debt (2025 - 2026) Analysis & Trends

Agomab Therapeutics has reported Total Debt for 2 years, with the latest figure at $7.8 million in Q2 2026.

  • On a quarterly basis, Total Debt changed N/A year-over-year to $7.8 million in Q2 2026; TTM through Jun 2026 was $7.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $7.6 million, changed N/A from the prior year.
  • Total Debt was $7.8 million for Q2 2026 at Agomab Therapeutics, up from $7.6 million in the prior quarter.
  • The five-year high for Total Debt was $7.8 million in Q2 2026, with the low at $7.6 million in Q4 2025.
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7.83 Mn
Dec 31, 2025 7.60 Mn
API Access

Agomab Therapeutics NV Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=AGMB&period=max&api_key=YOUR_API_KEY